Night-time intra-oesophageal bile and acid: a comparison between gastro-oesophageal reflux disease patients who failed and those who were treated successfully with a proton pump inhibitor

被引:18
作者
Hershcovici, T. [1 ,2 ]
Jha, L. K. [1 ,2 ]
Cui, H. [3 ]
Powers, J. [1 ,2 ]
Fass, R. [1 ,2 ]
机构
[1] So Arizona VA Hlth Care Syst, Neuroenter Clin Res Grp, Tucson, AZ 85723 USA
[2] Univ Arizona, Hlth Sci Ctr, Tucson, AZ USA
[3] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA
关键词
SYMPTOMS; IMPEDANCE; THERAPY; RESPOND; BILITEC; DAYTIME;
D O I
10.1111/j.1365-2036.2011.04583.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
P>Background Little is known about the contribution of bile and acid reflux to night-time symptoms generation in patients who failed PPI treatment. Aim To compare the degree of night-time oesophageal acid and bile [by the surrogate duodenogastroesophageal reflux (DGER)] exposure between gastro-oesophageal reflux disease (GERD) patients who failed and those who fully responded to PPI once a day while on treatment. Methods Gastro-oesophageal reflux disease patients were assigned to the PPI failure group if they continued to report symptoms >= 3/week and to the PPI success group if they were asymptomatic for the last 3 months while on PPI once a day. All patients underwent upper endoscopy and subsequently simultaneous 24-h oesophageal Bilitec and pH testing while on PPI treatment. Results Twenty-three patients were enrolled into the PPI failure group and 24 patients into the PPI success group. The percentage of night-time pH < 4 and the number of night-time acid reflux episodes were significantly higher in the PPI failure group as compared with the PPI success group. All night-time DGER parameters were similar between the PPI failure and PPI success groups. Conclusions Night-time oesophageal acid exposure is significantly higher in the PPI failure group vs. PPI success group. The degree of night-time bile reflux is similar in the two groups of patients with GERD.
引用
收藏
页码:837 / 844
页数:8
相关论文
共 36 条
[1]   Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis [J].
Adachi, K ;
Fujishiro, H ;
Katsube, T ;
Yuki, M ;
Ono, M ;
Kawamura, A ;
Rumi, MAK ;
Watanabe, M ;
Kinoshita, Y .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (11) :1191-1196
[2]  
American Gastroenterological Association, 2008, NEARL 40 PERC GERD P
[3]   Dietary interference with the use of Bilitec to assess bile reflux [J].
Barrett, MW ;
Myers, JC ;
Watson, DI ;
Jamieson, GG .
DISEASES OF THE ESOPHAGUS, 1999, 12 (01) :60-64
[4]  
Coron E, 2007, CURR OPIN GASTROEN, V23, P434
[5]   The Relationship Between the Prevalence of Nighttime Gastroesophageal Reflux Disease and Disease Severity [J].
Dean, Bonnie B. ;
Aguilar, Daniel ;
Johnson, Lawrence F. ;
Fass, Ronnie ;
Orr, William C. ;
McGuigan, James E. ;
Calimlim, Brian ;
Yan, Ning ;
Morgenstern, Diana ;
Dubois, Robert W. .
DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (04) :952-959
[6]   The role of proton pump inhibitors in gastro-oesophageal reflux disease [J].
Dekel, R ;
Morse, C ;
Fass, R .
DRUGS, 2004, 64 (03) :277-295
[7]   The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life [J].
Farup, C ;
Kleinman, L ;
Sloan, S ;
Ganoczy, D ;
Chee, E ;
Lee, C ;
Revicki, D .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (01) :45-52
[8]   Treatment of patients with persistent heartburn symptoms: A double-blind, randomized trial [J].
Fass, R ;
Sontag, SJ ;
Traxler, B ;
Sostek, M .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (01) :50-56
[9]   24-HOUR PH MONITORING IN SYMPTOMATIC PATIENTS WITHOUT EROSIVE ESOPHAGITIS WHO DID NOT RESPOND TO ANTIREFLUX TREATMENT [J].
FASS, R ;
MACKEL, C ;
SAMPLINER, RE .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1994, 19 (02) :97-99
[10]  
Fass R, 2005, ALIMENT PHARM THER, V22, P79, DOI 10.1111/j.1365-2036.2005.02531.x